First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor

Milvexian (BMS‐986177/JNJ‐70033093) is a small molecule, active‐site inhibitor of factor XIa (FXIa) being developed to prevent and treat thrombotic events. The safety, tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of milvexian were assessed in a two‐part, double‐blind, placebo‐con...

Descripción completa

Detalles Bibliográficos
Autores principales: Perera, Vidya, Wang, Zhaoqing, Luettgen, Joseph, Li, Danshi, DeSouza, Mary, Cerra, Michael, Seiffert, Dietmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841437/
https://www.ncbi.nlm.nih.gov/pubmed/34558200
http://dx.doi.org/10.1111/cts.13148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841437/
https://www.ncbi.nlm.nih.gov/pubmed/34558200
http://dx.doi.org/10.1111/cts.13148

Ejemplares similares